Makoski H B, Scherer E, Magnus L, Verbeek W
Strahlentherapie. 1978 Mar;154(3):169-73.
In the radiological hospital of Essen, 139 patients with malignant melanomas on the extremities have been submitted to an endolymphatic radionuclide therapy between May 29, 1970 and January 1, 1976. The survival rates of the different tumor stages are indicated and the changes of the survival curves since the last evaluation of August 31, 1973 are discussed. If the endolymphatic radionuclide therapy is applied, there is no risk of important side effects or complications. If an adequate surgical therapy has been effected prior to the radiotherapy, we consider the endolymphatic radionuclide therapy to be indicated above all in case of a malignant melanoma of the clinical stage I or II when the primary tumor is situated in the lower extremity.
在埃森放射医院，1970年5月29日至1976年1月1日期间，139例四肢恶性黑色素瘤患者接受了内淋巴放射性核素治疗。文中指出了不同肿瘤分期的生存率，并讨论了自1973年8月31日上次评估以来生存曲线的变化。如果采用内淋巴放射性核素治疗，不会有严重副作用或并发症的风险。如果在放疗前已进行了充分的手术治疗，我们认为内淋巴放射性核素治疗尤其适用于临床I期或II期、原发肿瘤位于下肢的恶性黑色素瘤病例。
